BRIEF-Taysha Gene Therapies Announces Progress Of Tsha-102 Pivotal Gene Therapy Program

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA

0.00

Jan 6 (Reuters) - Taysha Gene Therapies Inc TSHA.O:

  • TAYSHA GENE THERAPIES ANNOUNCES PROGRESS ACROSS TSHA-102 PIVOTAL GENE THERAPY PROGRAM IN RETT SYNDROME

  • TAYSHA GENE THERAPIES: COMPLETION OF DOSING IN REVEAL PIVOTAL TRIAL & ASPIRE TRIAL EXPECTED IN Q2 2026

  • TAYSHA GENE THERAPIES : LONGER-TERM SAFETY & EFFICACY DATA UPDATE FROM PART A OF REVEAL PHASE 1/2 TRIALS EXPECTED IN H1 2026

Source text: ID:nGNX5NrB6F

Further company coverage: TSHA.O


((Reuters.Briefs@thomsonreuters.com;))

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.